Overweight and obesity management

  • NICE guideline
  • NG246
  • Published: 

Register as a stakeholder

Download (PDF)

A practical guide to using medicines to manage overweight and obesity

The marketing authorisations for semaglutide and tirzepatide give the following examples of weight-related comorbidities, but this list is not exhaustive:

  • hypertension

  • dyslipidaemia

  • obstructive sleep apnoea

  • cardiovascular disease

  • prediabetes

  • type 2 diabetes mellitus.

For tirzepatide, refer to NHS England's interim commissioning guidance for NICE TA1026 for details on eligible patient cohorts, prioritisation strategy and phased implementation across specialist weight management services and primary care settings.

Weight-related comorbidities should be managed as soon as they are identified, do not wait until the person has lost weight to do this.

This page was last updated: